← SynDRA
ENASIDENIB
SynDRA canonical compound SYN0039139 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | IDH1 |
|---|
| Mechanism of action | isocitrate dehydrogenase inhibitor |
|---|
| Indication | acute myeloid leukemia (AML) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- IDH2
- IDH1
- IDH1; IDH2; IDH3A; IDH3B; IDH3G
Mechanisms of action (all sources)
- IDH2 INHIBITOR
- Isocitrate dehydrogenase [NADP], mitochondrial inhibitor
- IDH2 BINDER
- isocitrate dehydrogenase inhibitor
- Inhibitor
Drug classes
- Isocitrate Dehydrogenase 2 Inhibitors
- Isocitrate Dehydrogenase 2 Inhibitor
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- enasidenib mesylate
- AG-221
- CC-90007 Free Base
- CC-90007
- AG-221 mesylate
- AG-221 (IDH2 inhibitor)
- ENASIDENIB MESYLATE
- UNII-UF6PC17XAV
- Enasidenib (mesylate)
- UF6PC17XAV
- Enasidenib mesylate [USAN]
- Enasidenib mesylate (USAN)
- Enasidenib mesilate
- Enasidenib methanesulfonate
- Idhifa (TN)
- SCHEMBL16448052
- HY-18690A
- CS-7541
- 3T1SS4E7AG
- AG 221
- enasidenibum
- CHEBI:145374
- RefChem:58279
- L01XX59
- DTXCID401513509
- idhifa
- AG-221 (Enasidenib)
- Enasidenib [INN]
- MFCD29472245
- UNII-3T1SS4E7AG
- AG221
- AG-221(Enasidenib)
- AG-221; Enasidenib
- Enasidenib; AG-221
- ENASIDENIB [MI]
- Enasidenib (USAN/INN)
- Enasidenib [USAN:INN]
- AG-221(Enasidenib)?
Reported adverse events
- Dysgeusia
- Gastrointestinal disorder
- Nausea
- Vomiting
- Decreased appetite
- Differentiation syndrome
Look up ENASIDENIB in the interactive SynDRA portal →